1-20 of 38
Gideon Bollag
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

Bernice Matusow, Wayne Spevak, Chao Zhang, Yan Ma, Rafe Shellooe, James Tsai, Pei Pei Li, Pan Yu Chen, Gaston Habets, Christine Nichols, Parmveer Singh, Kerry Inokuchi, Jackie Walling, Jason Halladay, Gideon Bollag
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 660.
https://doi.org/10.1158/1538-7445.AM2024-660
Published: 22 March 2024
View article titled, Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
Journal Articles

Abstract 7201: Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

Connor A. Ott, Timothy Purwin, Manoela Tiago, Kristine Lou, Pan-Yu Chen, Somaneth Chowdhury, Glenn Mersky, Nir Hacohen, John Lamar, Claudia Capparelli, Gideon Bollag, Andrew Aplin
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7201.
https://doi.org/10.1158/1538-7445.AM2024-7201
Published: 22 March 2024
View article titled, Abstract 7201: Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
Journal Articles

Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Pan-Yu Chen, Bernice Matusow, James Tsai, Peipei Li, Hoa Nguyen, Gaston Habets, Gideon Bollag, Somenath Chowdhury
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7264.
https://doi.org/10.1158/1538-7445.AM2024-7264
Published: 22 March 2024
View article titled, Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models
Journal Articles

Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia

Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, Christopher R. D'Angelo, Avyakta Kallam, Matthew A. Lunning, Gregory Bociek, Julie M. Vose, Ben Powell, Gideon Bollag, Dalia El-Gamal
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6396.
https://doi.org/10.1158/1538-7445.AM2023-6396
Published: 04 April 2023
View article titled, Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia
Journal Articles

Abstract 2515: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and BRAF-inhibitor resistance

Orsolya Giricz, Yongkai Mo, Kimberly B. Dahlman, Xiomaris M. Cotto-Rios, Chiara Vardabasso, Hoa Nguyen, Bernice Matusow, Matthias Bartenstein, Veronika Polishchuck-Lee, Douglas B. Johnson, Tushar B. Bhagat, Rafe Shellooe, Elizabeth Burton, Gaston Habets, John M. Greally, Yiting Yu, Gideon Bollag, Paraic A. Kenny, Kith Pradhan, E. Richard Stanley, Emily Bernstein, Evripidis Gavathiotis, Brian L. West, Jeffrey A. Sosman, Amit Verma
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2515.
https://doi.org/10.1158/1538-7445.AM2018-2515
Published: 01 July 2018
View article titled, Abstract 2515: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and BRAF-inhibitor resistance
Journal Articles

Abstract 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition

Orsolya Giricz, Yongkai Mo, Caroline Y. Hu, Yiting Yu, Kith Pradhan, Matthias Bartenstein, Nandini Ramachandra, Veronika Polishchuck, Kimberly B. Dahlman, Tushar Bhagat, Hoa Nguyen, Bernice Matusow, Rafe Shellooe, Elizabeth Burton, Paraic Kenny, John Greally, Jeffrey Sosman, Gideon Bollag, Brian West, Amit Verma
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3332.
https://doi.org/10.1158/1538-7445.AM2017-3332
Published: 01 July 2017
View article titled, Abstract 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition
Journal Articles

Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors

Zoi Karoulia, Yang Wu, Tamer A. Ahmed, Qisheng Xin, Julien Bollard, Clemens Krepler, Xuewei Wu, Chao Zhang, Gideon Bollag, Meenhard Herlyn, James A. Fagin, Amaia Lujambio, Evripidis Gavathiotis, Poulikos I. Poulikakos
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1225.
https://doi.org/10.1158/1538-7445.AM2017-1225
Published: 01 July 2017
View article titled, Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors
Journal Articles

Abstract 1885: Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition

Orsolya Giricz, Yongkai Mo, Caroline H. Hu, Kimberly Dahlman, Nandini Ramachandra, Matthias Bartenstein, Kith Pradhan, Tushar Bhagat, Yiting Yu, Hoa Nguyen, Elizabeth Burton, Bernice Matusow, Gaston Habets, Rafe Shellooe, Gideon Bollag, Brian West, John Greally, Jeffrey Sosman, Paraic Kenny, Amit Verma
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1885.
https://doi.org/10.1158/1538-7445.AM2016-1885
Published: 15 July 2016
View article titled, Abstract 1885: Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition
Journal Articles

Abstract LB-008: KRAS engages AGO2 to enhance cellular transformation

Sunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Anastasia K. Yocum, Harika Gundlapalli, Yasmine White, Ari Firestone, Xuhong Cao, Saravana M. Dhanasekaran, Jeanne Stuckey, Gideon Bollag, Kevin Shannon, Nils Walter, Chandan Kumar-Sinha, Arul M. Chinnaiyan
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-008.
https://doi.org/10.1158/1538-7445.AM2016-LB-008
Published: 15 July 2016
View article titled, Abstract LB-008: KRAS engages AGO2 to enhance cellular transformation
Journal Articles

Abstract 4711: Broad anti-tumor activity of a novel BET bromodomain inhibitor

Yan Ma, Ben Powell, Jiazhong Zhang, Ying Zhang, Heidi Carias, Ullrich Schwertschlag, Gaston Habets, Prabha Ibrahim, Wayne Spevak, Chao Zhang, Gideon Bollag
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4711.
https://doi.org/10.1158/1538-7445.AM2016-4711
Published: 15 July 2016
View article titled, Abstract 4711: Broad anti-tumor activity of a novel BET bromodomain inhibitor
Journal Articles

Abstract IA32: Optimizing kinase inhibitors to treat cancer

Gideon Bollag
Journal: Cancer Research
Cancer Res (2016) 76 (3_Supplement): IA32.
https://doi.org/10.1158/1538-7445.FBCR15-IA32
Published: 07 April 2016
View article titled, Abstract IA32: Optimizing kinase inhibitors to treat cancer
Journal Articles

Abstract LB-058: Novel interactions of the RAS oncoprotein

Sunita Shankar, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Sethuramasundaram Pitchiaya, Shanker Kalyana-Sundaram, Anastasia Yocum, June Escara-Wilke, Harika Gundlapalli, Krishnapriya Chinnaswamy, Matthew Shuler, Anton Poliakov, Xiaoju Wang, Vishalakshi Krishnan, Yasmine White, Ari Firestone, Xuhong Cao, Saravana M. Dhanasekaran, Jeanne Stuckey, Gideon Bollag, Kevin Shannon, Nils G. Walter, Chandan Kumar-Sinha, Arul Chinnaiyan
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-058.
https://doi.org/10.1158/1538-7445.AM2015-LB-058
Published: 01 August 2015
View article titled, Abstract LB-058: Novel interactions of the RAS oncoprotein
Journal Articles

Abstract PR06: Integrated epigenomic profiling reveals widespread demethylation in melanoma and reveals CSF-1 Receptor as an aberrant regulator of malignant growth and invasion

Orsolya Giricz, Yongkai Mo, Caroline Hu, Kimberly Dahlman, Sanchari Bhattacharyya, Hoa Nguyen, Bernice Matusow, Tushar Bhagat, Yiting Yu, Rafe Shellooe, Elizabeth Burton, Gaston Habets, John Greally, Kenny Paraic, Jeffrey Sosman, Gideon Bollag, Brian West, Amit Verma
Journal: Cancer Research
Cancer Res (2015) 75 (14_Supplement): PR06.
https://doi.org/10.1158/1538-7445.MEL2014-PR06
Published: 16 July 2015
View article titled, Abstract PR06: Integrated epigenomic profiling reveals widespread demethylation in melanoma and reveals CSF-1 Receptor as an aberrant regulator of malignant growth and invasion
Journal Articles

CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

Jemima Escamilla, Shiruyeh Schokrpur, Connie Liu, Saul J. Priceman, Diana Moughon, Ziyue Jiang, Frederic Pouliot, Clara Magyar, James L. Sung, Jingying Xu, Gang Deng, Brian L. West, Gideon Bollag, Yves Fradet, Louis Lacombe, Michael E. Jung, Jiaoti Huang, Lily Wu
Journal: Cancer Research
Cancer Res (2015) 75 (6): 950–962.
https://doi.org/10.1158/0008-5472.CAN-14-0992
Published: 12 March 2015
View article titled, CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
Open the PDF for CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract LB-213: Discovery and molecular modeling of a novel mutation in the vemurafenib binding site of BRAF associated with therapeutic resistance in a patient with metastatic melanoma

Aleksandar Sekulic, Ashani T. Weeraratna, Jefferey L. MacKeigan, Amanpreet Kaur, Michael O'Connell, Megan L. Goodall, Michael Barrett, Elizabeth Lenkiewitz, Tara Holley, Victoria Zismann, Michael Gordon, Gideon Bollag, Chao Zhang, Jeffrey M. Trent
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): LB-213.
https://doi.org/10.1158/1538-7445.AM2014-LB-213
Published: 01 October 2014
View article titled, Abstract LB-213: Discovery and molecular modeling of a novel mutation in the vemurafenib binding site of BRAF associated with therapeutic resistance in a patient with metastatic melanoma
Journal Articles

Abstract A26: Integrated epigenomic profiling reveals widespread demethylation in melanoma, and reveals aberrant CSF-1 receptor expression as a regulator of malignant growth and invasion inhibited by PLX3397

Yongkai Mo, Orsolya Giricz, Caroline Hu, Kimberly Dahlman, Sanchari Bhattacharyya, Hoa Nguyen, Bernice Matusow, Tushar Bhagat, Yiting Yu, Rafe Shellooe, Elizabeth Burton, Gaston Habets, John Greally, Paraic Kenny, Jeffrey Sosman, Gideon Bollag, Brian L. West, Amit Verma
Journal: Cancer Research
Cancer Res (2013) 73 (3_Supplement): A26.
https://doi.org/10.1158/1538-7445.TIM2013-A26
Published: 01 May 2014
View article titled, Abstract A26: Integrated epigenomic profiling reveals widespread demethylation in melanoma, and reveals aberrant CSF-1 receptor expression as a regulator of malignant growth and invasion inhibited by PLX3397
Journal Articles

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (1): 153–161.
https://doi.org/10.1158/0008-5472.CAN-13-1816
Published: 05 January 2014
View article titled, Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Open the PDF for Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul Priceman, Brian West, Gideon Bollag, William McBride, Lily Wu
Journal: Cancer Research
Cancer Res (2013) 73 (9): 2782–2794.
https://doi.org/10.1158/0008-5472.CAN-12-3981
Published: 30 April 2013
View article titled, CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer
Open the PDF for CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer models

Hong Yang, Brian Higgins, Kenneth Kolinsky, Jiakui Li, Richard Margolis, Zenaida Go, Aruna Railkar, Kathryn Packman, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2156.
https://doi.org/10.1158/1538-7445.AM2012-2156
Published: 15 April 2012
View article titled, Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAF<sup>V600E</sup> colorectal cancer models
Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2012) 72 (4): 969–978.
https://doi.org/10.1158/0008-5472.CAN-11-1875
Published: 14 February 2012
View article titled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Open the PDF for Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation in another window
Includes: Supplementary data